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Copyright © 2009 JCBN Summary In comparison to the general population, individuals with diabetes suffer a 3- to 4-
fold increased risk for developing complications of atherosclerosis and vascular insufficiency.
This fact should be taken into account to develop a suitable determinant for the early detection
of these complications and subsequently reduce the adverse effect of type 2 diabetes. In vitro
experiments have shown that the products of glucose auto-oxidation and Amadori adducts are
both potential sources of Nε-(carboxymethyl)lysine (CML). Excessive formation of CML on
low density lipoprotein (LDL) has been proposed to be an important mechanism for the dys-
lipidemia and accelerated atherogenesis observed in patients with type 2 diabetes. It has been
postulated that the uptake of CML-LDL by LDL receptors is impaired, thereby decreasing its
clearance from the blood circulation. Alternatively, the uptake of these modified LDL particles
by scavenger receptors on macrophages and vascular smooth muscle cells (SMCs) and by
AGE receptors on endothelial cells, SMCs, and monocytes is highly enhanced and this, in turn,
is centrally positioned to contribute to the pathogenesis of diabetic vascular complications
especially coronary artery disease. The present review summarizes the up-to-date information
on effects and mechanism of type 2 diabetes-associated coronary atherosclerosis induced by
CML-LDL modification.
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Introduction
Type 2 diabetes can lead to cardiovascular damage
through a number of mechanisms, each of which in turn may
accelerate or worsen the others. Potential mechanisms of
how hyperglycemia may induce vascular injury include an
increased production of advanced glycation end products
(AGEs) and excessive oxidative stress [1]. Glycation, the
term adopted by the International Union of Biochemistry, is
given to any reaction that links a carbohydrate to free amino
groups of the proteins [2]. The term ‘AGEs’ is now used for
a broad range of Maillard reaction products such as Nε-
(carboxymethyl)lysine (CML). Hyperglycemia and hyper-
lipidemia which are associated with diabetes can lead to
irreversible nonenzymatic glycation of proteins and lipids
and formation of AGEs [3]. It has been reported that the
process of AGEs formation is accelerated by hyperglycemia
[4,  5]. Accumulation of AGEs with structural alterations
result in altered tissue properties that contribute to the
reduced susceptibility to catabolism [6], leading to the
gradual development of diabetic complications. It has been
reported that AGEs levels are increased in type 2 diabetic
patients with CAD [7].CML and LDL Abnormalities in T2DM
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Several interrelations have been shown between oxidative
stress and AGEs. Glycoxidation, a new term proposed by
Baynes, refers to AGEs formation through an oxidative
pathway [8]. CML modification of proteins is one of the
major glycoxidation products formed in vitro by the reaction
between glucose and protein [9]. Since CML is a major
product of oxidative modification of glycated proteins, it has
been suggested to represent a general marker of both
oxidative stress and long-term proteins damage in aging,
atherosclerosis, and diabetes [10]. Mykkanen et al. [11] have
shown that a dyslipidemic lipoprotein profile characteristic
of T2DM precedes the onset of diabetes. Lipoprotein
particles are modified by glycation in the presence of
hyperglycemia. The clearance of these glycated LDL particles
is prolonged, and thus they might be more readily oxidized,
leading to their increased uptake by macrophages [12]. In
fact, CML has been identified in glucose-modified LDL and
found in macrophage-induced foam cells of atherosclerotic
plaques [13, 14]. Thus, disturbance of lipid and lipoprotein
metabolism which commonly occur in diabetes almost
certainly contributes to the pathogenesis of vascular compli-
cations.
Type 2 Diabetes and Coronary Artery Disease:
General Overview
It has been suggested that type 2 diabetes be considered
as: “a state of premature cardiovascular death which is
associated with chronic hyperglycemia and may also be
associated with blindness and renal failure” [15]. Diabetes
predisposes its sufferers to cardiovascular disease (CVD) in
a number of ways. Subjects with diabetes are at increased
risk of atherosclerosis, and, to make matters worse, athero-
sclerosis in people with diabetes is accelerated in develop-
ment, more widespread and more severe. The same tradi-
tional risk factors for CVD are operative in type 2 diabetic as
in non-diabetic individuals. However, the effect of any given
risk factor on the incidence of CVD is greater in diabetic
than non-diabetic populations [16]. One of the major
vascular beds where atherosclerosis clinically manifests is
the coronary arteries leading to coronary artery disease
(CAD) [17].
The term coronary artery disease refers to the conse-
quences of oxygen deficiency in the myocardium caused by
the decrease or complete interruption of the blood supply,
generally originating from reduced blood flow from coro-
nary arteries and usually caused by atherosclerotic changes.
The process of athereogenesis was previously considered to
consist mainly of lipid accumulation within the artery wall.
Other processes, such as inflammation, are also involved
[18]. CAD, the most important manifestation of CVD,
represents a wide spectrum from angina pectoris, myocardial
infarction and sudden death to silent myocardial ischemia.
CAD is the major cause of mortality and morbidity in the
industrialized world [19]. T2DM and CAD share several
important characteristics—both conditions become more
prevalent with age, both are associated with obesity, an
abnormal serum lipid profile and a sedentary lifestyle.
Furthermore, it has been described that type 2 diabetes and
coronary artery disease conditions are insulin resistant
states associated with atherosclerosis [20]. Howard et al.,
however, concluded that higher levels of insulin sensitivity
are associated with less atherosclerosis in Hispanics and
non-Hispanic whites but not in blacks, and this effect is
partially mediated by traditional cardiovascular risk factors
[20]. Therefore, T2DM has been defined as a CAD risk
equivalent by the Adult Treatment Panel III of the National
Cholesterol Education Program (NCEP) [21].
Epidemiology of Coronary Artery Disease in Type 2
Diabetes
Approximately 17 million people in the United States or
6.2% of the population are diagnosed as having diabetes
mellitus [22]. The risks of developing CAD [23] as well as
long-term mortality as a result of CAD are higher in
individuals with diabetes than in those without diabetes [24].
For example, a recent meta-analysis showed that the rate of
fatal CAD is 3 times higher in diabetic patients than in non-
diabetic individuals [25]. In fact, CAD is the major cause of
mortality in type 2 diabetes. The overall prevalence of CAD,
detected by a variety of diagnostic methods, is reported to be
as high as 55% in individuals with diabetes compared with
2% to 4% in the general population [26].
CAD is not only more prevalent in diabetic patients
compared with the rest of the population but tends to be
more extensive, involving multiple vessels and is rapidly
progressive [27]. About 70% of deaths among type 2
diabetes patients result from CAD [28]. Compared with
CAD in nondiabetic persons, CAD in patients with diabetes
is more advanced at diagnosis and is generally characterized
by more extensive atherosclerosis with higher rates of left
ventricular dysfunction and cardiac events [26, 29]. Since
we are facing a dramatic, worldwide increase in the
incidence of type 2 diabetes [30], the cost for healthcare is
escalating [31]. The complications associated with T2DM
account for the majority of these expenditures and the
cardiovascular complications make significant contribution
to the cost of diabetes care [32].
Low Density Lipoprotein Metabolism, Glycoxidation
and Diabetes-Induced Atherosclerosis
Low density lipoprotein
In type 2 diabetes lipid abnormalities are almost the rule.
LDL cholesterol is a well-known risk factor for coronaryK.A. Ahmed et al.
J. Clin. Biochem. Nutr.
16
heart disease and is now recognized as the primary target of
lipid lowering therapy. Elevated LDL cholesterol has been
associated with CAD in follow-up studies [33,  34]. In-
creased LDL cholesterol predicts coronary heart disease
(CHD) in patients without macroangiopathy at baseline
indicating that elevated LDL cholesterol becomes important
after exclusion of high-risk patients with CHD at baseline.
More than 70% of people with type 2 diabetes have raised
LDL cholesterol levels [11]. The risk of a cardiovascular
event increases as the level LDL cholesterol level increases.
In the United Kingdom Prospective Diabetes Study, the risk
of either angina or a myocardial infarction in people with
type 2 diabetes increased 1.57 fold for every 1 mmol/l
increase in LDL cholesterol. Those with an LDL cholesterol
> 3.89 mmol/l were 2.3 times more likely to develop angina
or a myocardial infarction than people with an LDL
cholesterol < 3 mmol/l [33].
Advanced glycation end products and diabetic macroangio-
pathy
In diabetic patients increased AGEs levels have been
found in many tissues including dermal connective tissue,
small blood capillary walls and vessel walls of arterioles
and arteries [35, 36]. Vlassara and co-workers [37] have
administered AGE-modified albumin to healthy nondiabetic
rats and rabbits. After 2-4 weeks of AGE-administration,
animals displayed diabetes-like vascular complications: a
significant increase in vascular permeability, significant
mononuclear cell migration in subendothelial and peri-
arteriolar spaces and a defective endothelium-dependent
and -independent vasodilatation. AGEs were identified in
skeletal muscle arteries of streptozotocin-treated diabetic
rats within 4-6 weeks of induction of diabetes [38] and in
their mesenteric vessels within 3 weeks [39]. Moreover, it
has been shown in diabetic rats that some AGEs were found
in the aortic collagen after 4 and 12 weeks but this was
significantly increased by 20 weeks [40].
Advanced glycation end products formation is enhanced
in the presence of hyperglycemia in diabetes, by hyper-
lipidemia in atherosclerosis, and by oxidative stress in
chronic diseases, inflammation, neurodegenerative disorders
(such as Alzheimer’s disease) and renal failure as well as
under conditions where the turnover of lipids and proteins is
prolonged. AGE products accumulate in body fluids, cells,
tissues, and plasma [41]. In the cardiovascular system,
AGEs accumulation contributes to arterial stiffening, myo-
cardial relaxation abnormalities, atherosclerotic plaque
formation, and endothelial dysfunction. Physiological AGEs
in blood plasma have high renal clearances in normal
healthy subjects [41].
Immunohistochemical studies of human atherosclerotic
lesions have demonstrated intracellular AGEs deposition in
SMCs-derived foam cells in fatty streak and atherosclerotic
plaques in human aorta [42]. Significant extracellular AGEs
accumulation was also observed in advanced lesions [43].
AGEs formation on the extracellular matrix component of
the vessel wall can cause structural damage by decreasing
elasticity, increasing thickness, rigidity, and narrowing of
the vessel lumen [40,  44]. It has been shown that the
diminished arterial elasticity in humans with diabetes was
related to enhanced AGEs formation [45]. AGEs increase
collagen cross-linking leading to the arterial stiffness which
is commonly observed in normal ageing but at an accelerated
rate in diabetes [46]. Commonly found epitopes in AGEs
include CML, pentosidine and pyralline [47].
Role of AGEs receptors
The potential pathophysiological significance of AGEs is
associated with their accumulation in plasma, cells and
tissues and their contribution to the formation of cross-links,
generation of reactive oxygen intermediates, and interactions
with particular receptors on cellular surfaces [48]. In view of
the close association of AGEs with cells in the body and
their known adverse effects on cells, many studies have
focused on searching for AGE binding proteins. Binding
and internalization of AGE-modified proteins is facilitated
through several AGE-specific cell surface receptors [49].
Normally, AGE-modified proteins are repaired, replaced,
or degraded in vivo. The recognition and degradation of
such proteins is mediated by cellular receptors for AGEs
(RAGEs), which are present on certain critical target
cells such as monocytes, macrophages, endothelial cells,
mesangial cells and fibroblasts [50, 51]. Interaction of AGE
with RAGE on macrophages stimulates these cells to
produce and release cytokines, growth factors, proteolytic
enzymes, and increase expression of extracellular matrix
proteins and vascular adhesion molecules, which are all
required for normal tissue remodeling [52]. Excess produc-
tion of growth factors and cytokines plays an essential role
in both micro- and macrovascular alterations. Functional
alterations or saturation of the macrophage system would
allow anomalous tissue accumulation of AGEs leading to
reduced structural protein turnover, increased collagen
cross-links, and excessive degeneration and/or proliferation
of tissue components as observed in ageing and diabetes
[53].
In addition to RAGEs, several other cell surface receptors
for AGEs have been identified. These include macrophage
scavenger receptor types I and II, oligosaccharyl transferase-
48 (AGE-R1), 80K-H phosphoprotein (AGE-R2) and
galectin-3 (AGE-R3) [47]. Of these, RAGE has attracted
most attention, as it is to date the only AGE receptor
reported to have signal-transducing properties. An abundant
CML epitope in structurally heterogenous AGEs is specifi-
cally recognized by the RAGE V-domain [54]. In addition,
as RAGE is expressed in endothelial cells, vascular SMCsCML and LDL Abnormalities in T2DM
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and monocytes, it is centrally positioned to contribute to the
pathogenesis of diabetic vascular complications.
Binding of AGEs to endothelial cells increases expression
of adhesion molecules (VCAM-1 and ICAM-1) and tissue
factor in a RAGE-dependent manner resulting in vascular
hyperpermeability [55,  56] .  R A G E  i s  a  m e m b e r  o f  t h e
immunoglobulin superfamily and exists in two forms,
35 kDa and 45 kDa [57]. The 45 kDa form of RAGE has a
proteolytic property and is known as soluble RAGE
(sRAGE). It is used as a pharmacological agent to prevent
the vascular effects of AGEs (acts as an antagonist) in
experimental diabetes [58]. For example, vascular hyper-
permeability in diabetic rats was inhibited in the presence of
sRAGE in a dose-dependent manner [59]. In a murine model
of accelerated diabetic atherosclerosis, a six-week treatment
with sRAGE suppressed development of atherosclerosis in
a glycemia- and lipid-independent manner. Furthermore,
vascular lesions that formed in animals receiving sRAGE
were arrested at the fatty streak stage and the number of
complex atherosclerotic lesions was strikingly reduced [60].
A two-hit model for RAGE-mediated perturbation of
vascular function has been suggested [49, 61]. In the first
hit, prolonged presence of RAGE ligands changes vascular
properties priming the vasculature for a basal level of
activation. In the second hit, additional perturbation, such as
oxidized lipoproteins, ischemia, physical stress or inflam-
matory stimuli, results in exaggerated cellular response pro-
moting formation of vascular lesions rather than restitution
of vascular homeostasis. Furthermore, Anti-RAGE IgG can
also inhibit AGE-RAGE interaction and subsequently the
rise of vascular complications seen in diabetes [55].
Oxidative modification of LDL and atherosclerosis
Being the main carrier of cholesterol in blood, LDL is also
the principal lipoprotein causing atherosclerosis. Nishi and
co-workers have documented that vulnerable carotid
plaques from humans are greatly enriched in ox-LDL and
that plaque content of ox-LDL was 70 times the plasma
concentration [62]. Increased levels of ox-LDL are also
associated with increased carotid intima-media thickness
[63]. In addition, oxidation of LDL is not recognized by the
native LDL receptors and it is pereferably taken up via
receptors on macrophages of extrahepatic tissues, including
artery walls, resulting in cholesteryl esters deposition and
foam cells formation [64].
Oxidation of LDL enhances atherogenesis by a number of
different mechanisms, in particular by attracting the mono-
cytes into the vascular intima and transforming them into
foam cells and subsequent endothelial dysfunction as
illustrated in Figure 1. Oxidative modification of LDL has
also been shown to increase the ability of LDL to bind to the
extracellular matrix [65]. Therefore, oxidation of LDL plays
an important role not only in allowing LDL to be taken up
by macrophages leading to the formation of foam cells,
Fig. 1. A schematic illustration of foam cell formation in atherosclerosis. Circulating LDL cholesterol moves into the subendothelial
space. Trapped LDL is subjected to oxidative modification by vascular cells such as smooth muscle cells, endothelial cells, and
macrophages. Macrophages uptake modified LDL (ox-LDL) by scavenger receptors. In LDL overload, macrophages transform
themselves into foam cells which become necrotic due to the accumulation of oxidized LDL. Oxidized LDL also results in
endothelial dysfunction and injury. Local inflammation increases the entry of LDL and monocytes. (Adapted from Diaz et al.,
N. Engl. J. Med., 1997. [68]).K.A. Ahmed et al.
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but also in promoting entry of monocytes/macrophages to
the sub-intimal space where the process of LDL uptake
occurs. However, oxidation of LDL apparently leads to
possibly a very large array of consequences other than the
generation of foam cells thought to be important in athero-
genesis. For example, the oxidative modification of LDL has
also been shown to be a chemoattractant for monocytes and
to be cytotoxic to endothelial cells, as well as to inhibit nitric
oxide-induced vasodilation [66]. Protection of LDL from
oxidation could increase nitric oxide bioactivity and
bioavailability and improve endothelium-dependent vaso-
motor, anti-inflammatory, and anticoagulant properties of
the endothelium [67].
A prototypical protein target for oxidants in cardio-
vascular disease is the LDL and oxidation of LDL has been
considered as an important mechanism for the development
of atherosclerosis [69, 70]. It is noteworthy that oxidized
lipoproteins have been implicated in the development of
many diseases ranging from diabetes to arthritis. Conse-
quently, there has been a vast amount of interest in
evaluating factors that influence the LDL oxidation, as well
as development of pharmacological agents and antioxidants
that could reduce the oxidative modification of LDL.
LDL peroxidation is probably the most extensively
investigated free radical-induced chain reaction [71,  72].
The earliest step in the generation of oxidative modified
LDL is peroxidation of polyunsaturated fatty acids (PUFAs)
in LDL phospholipids. Thus, PUFAs are particularly
susceptible to peroxidation and once the process is initiated,
it proceeds as a free radical-mediated chain reaction
involving initiation, propagation and termination [73].
Each single substrate radical may result in conversion of
multiple fatty acid side chains into lipid hydroperoxides.
The length of the propagation chain before termination
depends on several factors such as the oxygen concentration
and the amount of chain-breaking antioxidants present.
Hydroperoxides are fairly stable molecules, but their
decomposition can be stimulated by high temperatures or
by exposure to transition metal ions (iron and copper ions).
Decomposition of hydroperoxides generates a complex
mixture of secondary lipid peroxidation products such as
malondialdehyde (MDA) and 4-hydroxynonenal.
LDL glycation and glycoxidation
A multitude of secondary complications of T2DM have
been attributed to nonenzymatic glycation. Exposure of
LDL to advanced glycation end products can prolong its
half-life and then it will be trapped in the vascular wall
where it is more susceptible to oxidation [74]. LDL has a
special place in studies of glycation and oxidation in
diabetes because it is a strong risk factor for atherosclerotic
vascular diseases. LDL of diabetic patients with poor
glycemic control is more susceptible to oxidation when
compared to LDL of normal subjects [75].
Glycation of LDL particles can alter their structure,
function, and their susceptibility to oxidation and hence
affect their atherogenic potential. One of the most compelling
lines of evidence, which allows us to consider glycated
LDL atherogenic, is the in vitro and in vivo studies which
suggested the altered biological activity of glycated
lipoproteins. Incubation of LDL with glucose leads to AGE
formation on both the lipid and apoprotein components.
Klein group has shown that recognition of LDL from
diabetic patients with poor glycemic control by human
fibroblasts was also impaired, supporting the role of
glycation in altering recognition of LDL by the classical
LDL receptor [76]. Subsequently, incubation of macro-
phages with glycated LDL results in transformation of these
macrophages into cholesterol loaded foam cells. Glycated
LDL uptake resulted in increased cholestryl esters synthesis
in macrophages leading to increased intracellular cholestryl
esters accumulation. Lipid peroxidation is known to induce
cross-linking of collagen with a high rate in the presence of
high glucose [77]. Glycated collagen was shown to be
capable of covalently trapping LDL (e.g. in the arterial wall)
causing it to be oxidatively modified by free radicals [78].
The increase of plasma levels of LDL and/or changes
in their subfractions are associated with an increase of
atherogenic risk. In the diabetic patients, although plasma
LDL level often stays within the normal range, alterations
take place in the lipoproteins components such as diameter,
density, and lipid composition that make it more atherogenic
[79]. To these, the nonenzymatic glycation that modifies the
LDL and affects its metabolism resulting in increase in its
potential atherogenicity must be added. In this sense, the
glycation is directly linked to the oxidation of the LDL in the
arterial wall [80]. Modifications to LDL such as oxidation
and glycation are strongly implicated in the pathogenesis
and progression of atherosclerosis [81]. Accumulated
evidences in the last years suggest the combination of
processes of nonenzymatic glycation and oxidation by free
radicals acting on the lipoproteins, would contribute to
generate a greater atherogenic risk in the diabetic patients,
as proposed by Bayne [8]. The combinations of these two
reactions, collectively known as glycoxidation, generate
products that can be especially atherogenic [80, 82]. The
interaction between glycation and oxidation provides a
probable explanation for the increase of atherosclerosis
frequently associated with diabetes.
The development of atherosclerosis is accelerated in
patients with diabetes mellitus, and LDL in a diabetic state is
susceptible not only to oxidation [83] but also to glycation
[84]. In the diabetic patients several types of modified
LDL molecules have been detected, including glycated
LDL, oxidized LDL, and glycoxidized LDL. Immuno-
histochemical studies on human atherosclerotic lesions haveCML and LDL Abnormalities in T2DM
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shown that AGEs and oxidized LDL are colocalized in the
cytoplasm of macrophage-derived foam cells [13].
The contribution of advanced glycation to the oxidative
modification of LDL was first observed in an in vitro study
[85]. Isolated human LDL was incubated with glucose (in
presence of metal ions) and analyzed for both advanced
glycation and oxidative modification. Incubation of LDL
with 200 mM glucose for 3 days resulted in the formation of
readily measurable levels of AGEs on both apoprotein
(Apo-B) and lipid. This study indicated also that lipid-linked
AGEs formed more rapidly than ApoB-AGEs and measure-
ments of oxidative modification further showed that LDL
was oxidized concomitantly with the formation of AGEs.
Moreover, increased levels of peroxidation products are
detected in glycated or cell-modified LDL particles, which
have been known as minimally modified LDL [86]. For
better explanation the relationship between advanced
glycation and LDL oxidation in vivo, Bucala et al. analyzed
LDL from both diabetic and nondiabetic individuals by an
AGE-specific ELISA [85]. Their investigations revealed
increased levels of both phospholipids-AGEs and apoB-
AGEs of the LDL molecules from diabetic patients
compared to healthy controls.
Role of scavenger receptors
Atherosclerosis is an inflammatory disease [87] and
macrophages are present at all stages of the disease [88].
Animal studies, using several different models of
atherosclerosis, support a key role for macrophages in the
development and progression of atherosclerosis. In addition
to their contribution in the modification of LDL [81, 87],
macrophages, in their role of scavenging tissue and cellular
debris, can take up the modified LDL via scavenger receptors
[89]. Scavenger receptors recognize chemically and bio-
logically modified lipoproteins, typically acetylated LDL
and oxidized LDL. Unlike LDL receptor, the expression of
scavenger receptor is not down regulated by cellular
cholesterol content and, therefore, results in the intracellular
lipid accumulation and consequently induces foam cell
formation. Recent studies showed that, at least in macro-
phages, macropinocytosis has been shown to operate in the
uptake of native LDL too, in the process leading to foam cell
formation [90]. However, important in this respect is that
modified LDL is taken up faster by macrophages than native
LDL.
Monocyte-derived macrophages endocytose modified
LDL via multiple receptors, including both class A (SR-A)
and class B (SR-BI and CD36) scavenger receptors [91, 92],
class E receptor (lectin-like oxidized LDL receptor-1), and
lipoprotein lipase [93,  94]. Other scavenger receptors
include class D receptor (CD68) and scavenger receptors
for phosphatidylserine and oxidized lipoprotein (SR-PSOX),
which mediate binding and uptake of ox-LDL [95–97].
Uptake of lipoproteins in excess of its metabolism results in
the formation of cholesteryl esters in macrophage derived-
foam cells. Similarly, foam cells can develop from vascular
SMCs by the uptake of oxidized LDL via class A and class
B scavenger receptors [98, 99]. Lipid-laden macrophages
have been shown to exhibit strong immunoreactivity to
CD36, but only low or moderate levels of immunoreactivity
to SR-A [100], suggesting that CD36 could be the pre-
dominant macrophage receptor for ox-LDL in human
atherosclerotic lesions.
Diabetes exacerbates the uptake of modified LDL by
foam cells via several mechanisms. Firstly, diabetes causes
a proatherogenic dyslipidemia resulting in high serum
triglyceride levels, reduced levels of HDL, and increased
number of small dense LDL particles [101]. Secondly,
diabetes increases the expression of macrophage class B
scavenger receptor CD36 [102], which enhances oxidized
LDL endocytosis. Thirdly, hyperglycemia increases glycoxi-
dation, resulting in increased levels of oxidized and glycated
LDL, which increases ligand availability for scavenger
receptors and lipoprotein lipase [85]. Modification of
proteins by oxidation, glycation, or glycoxidation has been
proposed to impair binding of LDL to the LDL receptor, and
increase binding and endocytosis by unregulated scavenger
receptor pathways.
Nε-(Carboxymethyl)lysine Accumulations in Diabetes-
Associated Complications
Nε-(Carboxymethyl)lysine: formation and chemical properties
AGEs form a large group of heterogenous compounds of
which only a few have been identified. Nε-(Carboxymethyl)
lysine, a product of glycation and oxidation in vivo, is
generated by oxidative cleavage of the Amadori product
threulosyl-lysine and is also a product of metal-catalyzed
oxidation of LDL or peroxidation of polyunsaturated fatty
acids in the presence of fructose-lysine. Thus, CML is
known to be a glycoxidation product which means that it
requires oxidation reactions for their formation from glucose
[8]. Although CML is the smallest one of the AGE
modifications, it might be functionally relevant. It leads to a
change in charge, since, after modification, the former
positively charged lysine residues carry a negatively charged
carboxylic group.
CML is an irreversible protein modification which is
stable to acid hydrolysis and can be quantified from protein
hydrolysates. It has been reported that CML binds to RAGE
and activates cell-signaling pathways [54]. Moreover, co-
localization of CML with adducts derived from products of
lipid peroxidation, such as 4-hydroxynonenal and MDA,
supports the concept that lipid peroxidation itself, in
addition to and apart from advanced glycation, triggers the
formation of CML [103]. CML contents of proteins exist inK.A. Ahmed et al.
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several tissues such as lung, skin, bone, and blood vessles.
However, CML epitopes are not uniformly distributed in
these tissues, with more intensely staining of the elastic
fibres of blood vessels and skin than surrounding tissues
[35].
Nε-(Carboxymethyl)lysine and vascular complications of
diabetes
Inefficient clearance of degraded low molecular weight
AGE-rich peptides and recirculation of these ‘toxic’
molecules might be responsible for vascular damage in
diabetic patients. It has been described that highly modified
AGE proteins are able to bind to macrophage scavenger
receptors [104] and receptor for AGE (RAGE) [105].
Studies have identified CML of AGE proteins as a ligand
for RAGE [106, 54]. Although other studies have revealed
that CML proteins are not recognized by scavenger receptors
[107] and were unable to interact with RAGE or activate an
inflammatory response in RAGE-expressing cells [108],
these observations have not been confirmed in other
laboratories. Further studies are required to clarify this issue
of CML interaction with RAGE and macrophage scavenger
receptors.
Since specific CML antibodies have become available,
several studies have demonstrated the accumulation and
distribution of CML in atheromatous lesions [109, 110] and
observed within artheroslerotic plaques, in foam cells [35,
111], in a variety of chronic degenerative, chronic inflam-
matory diseases [112], and recently in human heart valves
[113] as well as in the heart tissue of diabetic patients [114].
CML has become a key marker of protein modification in
response to glyoxidative, lipoxidative and carbonyl stress in
vitro. This has led to suggestion that it could also represent a
biomarker for systemic or local oxidative stress in tissue
Fig. 2. Proposed model of CML formation on LDL in the blood circulation and in the subendothelial space. CML can be formed on
low density liboproteins in the blood circulation and trapped CML-LDL as well as CML-LDL formed in extracellular matrix
will be taken up by macrophages through scavenger receptors followed by macrophages transformation into foam cells. Other
processes in this figure are discussed in the text.CML and LDL Abnormalities in T2DM
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lesions  in vivo [ 115]. CML content increases with the
chronological age of proteins [4,  116] and detected in
patients with diabetes mellitus [35]. Figure 2 showed the
different pathways of CML formation on LDL and their
uptake by macrophages. Hyperglycemia leads to glycation
of serum proteins including LDL and an increase in
endothelial glucose concentration via GLUT-1 transporters.
Increased intracellular glucose leads to the formation of
reactive carbonyl species (RCS) such as methylglyoxal,
glyoxal, and 3-deoxyglucosone, which may be released into
the bloodstream or the subendothelial space and react with
LDL to form CML-LDL. In both blood circulation and
arterial intima, LDL is subjected to glycoxidation and CML
formation. CML-LDL is recognized by endothelial cell
through AGE receptor (RAGE) leading to reactive oxygen
species (ROS) formation. Monocytes and CML-LDL particles
cross the endothelium and can become trapped in the
extracellular matrix followed by CML-LDL binding to
scavenger receptors on the macrophages, which undergo
foam cell formation and, thus, atherosclerosis lesions.
In diabetes, the rate of CML formation is accelerated as
compared to that seen in aging and in some studies, CML
seems to correlate with the severity of diabetic complica-
tions independent of age [117, 118]. CML has been reported
to stimulate superoxide radical and H2O2 generation via
activation of NADPH oxidase in human endothelial cells
[119]. The cytoplasmic domains of foam cells also contain
the CML epitopes, which may be due to receptor-mediated
uptake and degradation of AGE-modified proteins by
macrophages within plaques [13].
Since CML can be formed from glycation and lipid
peroxidation reactions, the observed increase in CML in
diabetes may be accounted for either an increase glycation
or increased oxidative stress. However, it has been reported
that CML can be formed by a nonoxidative mechanism and
its elevations in diabetic serum support the notion that the
nonoxidative glycation of proteins may contribute to AGE
accumulation in diabetes [116,  120]. The observation of
CML accumulation in diabetic muscle is in good accordance
with this general notion. The vasculature is the preferred
environment for localization of CML accumulation in
diabetic macroangiopathy. Although several studies showed
CML elevations in diabetic microvascular complications,
there is ongoing debate about the effect of CML on macro-
vascular diseases resulting from T2DM.
Although Kilhovd and co-workers found that serum
AGEs levels increase in patients with CHD and T2DM
[121], little data are available on the relationship between
serum CML and macrovascular complications in individuals
with T2DM. Kiuchi et al. showed that serum AGE concen-
trations were higher in type 2 diabetic patients with
obstructive CAD than in patients without obstructive CAD,
and higher than in non-diabetic patients with and without
obstructive CAD. Furthermore, serum AGE was associated
with the degree of coronary arteriosclerosis in type 2
diabetic patients with obstructive CAD. These results
indicate that serum AGE concentrations may be associated
with long term poor glycaemic control and reflect the
severity of coronary arteriosclerosis in type 2 diabetic
patients [7]. Miura et al. pointed out that serum non-CML
AGE levels were significantly associated with the severity
of diabetic nephropathy and retinopathy, suggesting a role of
non-CML AGE in the progression of microvascular compli-
cations [122]. The finding of the relationship between blood
CML levels and the severity of microangiopathy suggested
that the blood CML levels are related to the severity of both
nephropathy and retinopathy [123]. Wautier et al. demon-
strated that in type 2 diabetic patients with retinopathy or
microalbuminuria, serum CML levels were significantly
higher, and even more elevated in patients with both compli-
cations [124].
Our work on CML has revealed a significant role of CML
levels on the development of ischemic heart disease in
patients with type 2 diabetes [125]. Since it has been
established that CML levels are increased in the serum with
aging [126], our findings exclude the effect of age on CML
levels in type 2 diabetic patients with ischemic heart disease.
In a more recent work, it has been shown for the first time
the significant predictive power of high serum CML concen-
trations to CAD in type 2 diabetes patients and this associa-
tion between CML and CAD is independent of other risk
factors [127].
We have also studied the effect of increased CML content
of LDL (unpublished data), enhanced LDL oxidation, and
the high CML levels on the defective uptake of LDL by its
receptor in T2DM patients with CAD [127]. Our measure-
ments have revealed that LDL particles obtained from
diabetes patients without CAD, AGE-LDL, and oxidized-
LDL have similar uptake and distribution in the cytoplasm
of Hepatoma (HepG2) cells. These LDL particles did not
appear to be defective in terms of their ability to bind to the
LDL receptor, rather, their interaction with the LDL receptor
was reduced when compared to native LDL. On the other
hand, the binding and uptake of LDL from T2DM subjects
with CAD were impaired, indicating that LDLs obtained
from these patients may have increased atherogenic potential.
CML-LDL particles may be more atherogenic than the
classic oxidized- and glycated-LDL due to the concomitant
effect of both the chronic state of diabetes and oxidative
stress in type 2 diabetes patients with artery disease [111,
128]. Nonenzymatic glycation of proteins including LDL
may be closely correlated to lipid peroxidation in the arterial
intima as explained by localization of CML in the cytoplasm
of macrophage-derived foam cells in atherosclerotic lesions
[13]. Furthermore, Sakata et al. [ 14] have described the
synergistic effect of chronic high blood glucose and oxida-K.A. Ahmed et al.
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tive stress on producing CML-LDL. These results also
suggest that LDL particles from T2DM patients with CAD
have similar glycoxidative behaviors and properties as
CML-LDL prepared in vitro and these modified LDL
molecules were not found in diabetes patients without CAD.
Conclusions
In summary, this review shows the significant association
between serum CML levels and type 2 diabetes complica-
tions, especially CAD and that raised CML levels may
reflect the enhanced oxidative stress in these patients due to
prolonged higher blood glucose levels in diabetic CAD
patients. As the prevalence of diabetes increases globally,
laboratory findings will continue to play a major role in the
early diagnosis and subsequently better management of the
diabetic vascular complications. Since it has been estab-
lished that CML is accumulated in atherosclerotic lesions of
diabetic subjects, elevation of carboxymethylated-LDL
(CML-LDL) might be the rule in this process. From previos
investigations and our study on LDL metabolism, it is
concluded that carboxymethylation of LDL may be largely
responsible for the defective LDL uptake by LDL receptor
rather than AGE-LDL or ox-LDL. The impairment in
receptor-specific metabolism might be attributed to the
findings that LDL molecules of diabetic CAD patients
exhibit higher CML content levels than diabetics without
complications, indicating that both type 2 diabetes and CAD
are superimposed. Moreover, the studies on modified LDL
metabolism not only confirmed the previous observations
that glycoxidized LDL is present in vivo but rather, it shows
that glycoxidized LDL may be of CML-epitope that could
be found in higher concentrations in patients with T2DM
and CAD than diabetes patients without macrovascular
complications especially CAD. Thus, CML may play a
crucial role in the development of CAD in patients with
T2DM and may be considered as an independent endo-
genous marker of interest for early detection of CAD in type
2 diabetic patients. In view of its cumulative effect on
impairment of lipoprotein metabolism, CML may serve as
an important target for glycemic control in these patients.
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